Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by amorakon Apr 10, 2011 2:09pm
754 Views
Post# 18410873

RE: RE: RE: so loosely traded...

RE: RE: RE: so loosely traded..."the issue is the volume is way too low for us to get excited...."

Kind of a funny statement, that was. It's sort of like Yogi Berra's statement about the NY restaurant, "Nobody goes there anymore, it's too busy."

The fact is, the lack of excitement causes the low volume, not the other way around. But you're right, as soon as some excitement is generated, this will pop, not to $6, I don't think, but $4 maybe. Even when the ASSURE go-date is announced we'll still have to wait a year for results. That's not all that exciting.

There are some things that could create the excitement, perhaps a funding JV or some other interesting financing. More likely we'll see 3rd party news about research or trial results that indirectly confirm RVX's work and value but that don't compete directly with RVX, something like the Cerenis trial.

Stagnant money is never exciting but the trouble with RVX is that we can never predict when some oddball event or circumstance will cause this to run. Because ASSURE success will make this so valuable, there really isn't much alternative but to hold the stock and your nose at the same time. Buying this at $2 rather than $4 or more results in owning far more shares for your money and if we think that RVX will be successful, then buying it at $2 is a very rational thing to do. On any of the several runs this will have before this is over you can take some money off the table or just sit and admire your own wisdom for buying at $2. It's all good.
Bullboard Posts